JAK/TYK2
Day 4 was a half day closeout to the EULAR 2023 Congress. For me the big presentations were the late breaking abstracts, although there were other review and abstract sessions for those remaining.…
10 months 2 weeks ago
An update on JAK inhibitors and cardiovascular risks
Dr. Antoni Chan ( @synovialjoints ) shares #EULAR23 developments on JAK/TYK2 inhibitors.
https://t.co/VovWE2OuXW https://t.co/QXKZLh5RuK
10 months 3 weeks ago
JaL1/TYK2 inhibitor vs Tofacitinib in #RA at #EULAR2023 phase 2. @RheumNow https://t.co/0F3JQ9dVMA
10 months 3 weeks ago
Abstracts talking about #RA and JAKs and Biologic comparisons
Huge number of pts to analyze this aftrr the initial NEJM study. Abstract summary pics below
@RheumNow https://t.co/jl5S4fLq19
Podcasts
Nonradiographic Axial Spondyloarthritis - Dr. Eric Ruderman
Canary In A Coal Mine (4.19.2024)
Vasculitis Faculty Panel Q&A
Poster Hall